Last reviewed · How we verify

NCT05936437

Clinical Benefits and Safety of Combined Polynucleotides and Hyaluronic Acid - Newest - for Acne Scars Treatment

Completed NA Last updated 12 August 2025
What this trial tests

NA trial testing Subjects treated with Newest medical device in Atrophic Scar in 30 participants. Completed in 24 July 2025.

Timeline
16 November 2023
Primary endpoint
24 July 2025
24 July 2025

Quick facts

Lead sponsorMastelli S.r.l
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date16 November 2023
Primary completion24 July 2025
Estimated completion24 July 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Mastelli S.r.l

Who can join

Adults 20 to 60, any sex, with Atrophic Scar. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study wants to evaluate the efficacy and safety of a medical device combining "Polynucleotide Highly Purified Technology" (PN-HPT™) and hyaluronic acid (Newest-Mastelli S.r.l) for treating moderate-to-severe atrophic post-acne scars.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mastelli S.r.l trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05936437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing